CIK 0000906709
- Non-accelerated filer
- Smaller reporting company
NEKTAR THERAPEUTICS
Sign in to watch- Ticker
- NKTR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943134940
- Phone
- +1 415-482-5300
- Business address
- 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158
- Former names
- INHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS
- 4 Open-market sale Chief Legal Officer sold 11,040 shares at $1.01 ($11,150)
- 4 Open-market sale President & CEO sold 23,774 shares at $1.01 ($24,012)
- 5 Insider Annual Insider Trading Report
- 5 Insider Annual Insider Trading Report
- 5 Insider Annual Insider Trading Report
- 5 Insider Annual Insider Trading Report
- 5 Insider Annual Insider Trading Report
- 4 Open-market sale Chief Legal Officer sold 49,962 shares at an average $0.90 ($44,800)
- 4 Open-market sale Chief R&D Officer sold 51,115 shares at $0.94 ($48,048)
- 4 Open-market sale President & CEO sold 132,030 shares at an average $1.00 ($131,650)
- 4 Grant or award Chief R&D Officer acquired 135,000 shares (grant or award)
- 4 Grant or award Chief Legal Officer acquired 165,938 shares (grant or award)
- 4 Grant or award President & CEO acquired 410,625 shares (grant or award)
- 4 Open-market sale Chief R&D Officer sold 7,785 shares at $1.01 ($7,863)
- 4 Open-market sale Chief Legal Officer sold 6,407 shares at $1.01 ($6,471)
- 4 Open-market sale President & CEO sold 16,278 shares at $1.01 ($16,441)
- 4 Open-market sale Chief R&D Officer sold 6,866 shares at $1.28 ($8,788)
- 4 Open-market sale Chief Legal Officer sold 5,651 shares at $1.28 ($7,233)
- 4 Open-market sale President & CEO sold 14,881 shares at $1.28 ($19,048)
- 4 Planned sale Director sold 19,500 shares at $1.20 ($23,400)
Page 3 of 49 · 968 filings